Cheng CH, Hao WR, Cheng TH. Exploring Xiaojianzhong decoction's potential in gastric cancer treatment: Integrative insights and experimental validation. World J Gastrointest Oncol 2024; 16(12): 4553-4558 [DOI: 10.4251/wjgo.v16.i12.4553]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4553-4558 Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4553
Exploring Xiaojianzhong decoction's potential in gastric cancer treatment: Integrative insights and experimental validation
Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, Taipei 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan
Co-first authors: Chun-Han Cheng and Wen-Rui Hao.
Author contributions: Cheng CH, Hao WR, and Cheng TH have contributed to this editorial; Cheng CH and Hao WR primarily responsible for writing, and Cheng TH overseeing revisions. All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: July 24, 2024 Revised: September 2, 2024 Accepted: September 5, 2024 Published online: December 15, 2024 Processing time: 110 Days and 17.2 Hours
Abstract
Gastric cancer (GC) remains a formidable global health concern with significant morbidity and mortality rates, despite the fact that numerous advances have been made to improve conventional therapies. Xiaojianzhong decoction (XJZ), a traditional Chinese medicine, has garnered academic attention as a multicomponent, multitarget approach to managing GC. The present editorial explores the potential of XJZ in the treatment of GC through a comprehensive analysis of network pharmacology and experimental validation. Network pharmacology was used to identify key molecular targets of XJZ, including interleukin 6, prostaglandin-endoperoxide synthase 2, and matrix metalloproteinase 9, and in vitro experiments were used to confirm the efficacy of XJZ in inhibiting cell proliferation, inducing apoptosis, and modulating gene expression associated with GC progression. This editorial highlights XJZ as a promising therapeutic strategy for GC and indicates a need for further clinical exploration and validation of its efficacy.
Core Tip: This editorial integrates network pharmacology insights with rigorous experimental validation to highlight the potential of Xiaojianzhong decoction as a multifaceted therapeutic approach for gastric cancer.
